Given the biologic effects of the anti–IL-6 agents, gp130 and tocilizumab, we tested these agents in our stasis model of VT after a thrombus had formed to mimic human translation of post-DVT therapy. This evidence concerns the gene IL6 and deep vein thrombosis.